Sector News

Struggling Endo's latest restructuring puts 90 staffers out of work

January 26, 2017
Life sciences

It hasn’t been a happy new year so far for Endo, which is starting 2017 the same way it closed out 2016: with layoffs.

The Dublin drugmaker has kicked off its latest phase of restructuring, which will claim 90 jobs and cost the company $15 million to $20 million, it said Thursday. The affected positions fall primarily within corporate functions and branded pharma R&D at the company’s Malvern, Pennsylvania, and Chestnut Ridge, New York, bases.

The expected results? $40 million to $50 million in pretax cost savings by the end of this year, the company said.

It’s the third round of recent layoffs for struggling Endo, which is looking to stage a comeback under new leadership. Last May, the company announced it would slash 740 jobs in Charlotte, North Carolina, and Huntsville, Alabama, in an effort to save money across its generics manufacturing network. And in December, it unveiled plans to sideline its once-core pain business, putting 375 sales reps and other staffers out of a job in the process.

This time around, the job cuts will “better align” the corporate functions and branded pharma R&D units with the recently edited generics and branded pharma divisions, Endo said in a statement. The bright side? These departments will be “the last of the organizations to be impacted,” CEO Paul Campanelli said in a statement.

Endo, like many of its specialty peers, has had a rough go of it lately. Last year, it hacked down its full-year guidance to well below Street forecasts, citing new market rivals, greater-than-expected generics price erosion and regulatory delays.

Since then, the company has bid some top execs farewell; in September, Campanelli, a former Par Pharmaceutical CEO, took the helm from Valeant vet Rajiv De Silva, and CFO Suketu Upadhyay made his own exit the following month.

By Carly Helfand

Source: Fierce Pharma

comments closed

Related News

September 25, 2022

Rise of the machines: Novo Nordisk pledges $200M to create first quantum computer for life sciences

Life sciences

Big Pharma has long seen the potential for AI and machine learning to accelerate drug development. But Novo Nordisk is going a step further by channeling $200 million toward the creation of a computer that will outrun anything in existence.

September 25, 2022

Mount Sinai AI uncovers new brain analysis method to predict dementia, Alzheimer’s disease

Life sciences

Current methods for diagnosing Alzheimer’s disease rely on a complex combination of self- and caregiver-reported symptoms, a physical examination and either a PET scan or a spinal tap to look for evidence of amyloid plaque build-ups in the brain. But a new artificial intelligence-based method may make the diagnostic process a much more objective one.

September 25, 2022

New AstraZeneca-backed report finds big money behind diverse owners and entrepreneurs in Europe

Life sciences

There is lots of talk about diversity and inclusion in business, including in pharma and medtech. A new report by the Open Political Economy Network (OPEN), a think tank focusing on migration and diversity, released its “Minority Businesses Matter: Europe” report highlighting the successes and challenges of ethnic minority-owned businesses in Europe.